New drug combo tested against rare, aggressive eye cancer
NCT ID NCT04552223
Summary
This study tested whether combining two immunotherapy drugs, nivolumab and relatlimab, could shrink tumors in people with metastatic uveal melanoma, a rare and hard-to-treat cancer that starts in the eye and spreads. The trial involved 27 patients who had not received similar treatments before. Researchers gave the drugs through an IV every four weeks and tracked how patients responded and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.